TRVI vs. CALT, DAWN, PRAX, ANIP, SPRY, AUPH, SNDX, COLL, SYRE, and ELVN
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), Praxis Precision Medicines (PRAX), ANI Pharmaceuticals (ANIP), ARS Pharmaceuticals (SPRY), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), Spyre Therapeutics (SYRE), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry.
Trevi Therapeutics vs.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
Trevi Therapeutics has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.
Trevi Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Trevi Therapeutics' return on equity of -63.31% beat Calliditas Therapeutics AB (publ)'s return on equity.
2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 24.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Trevi Therapeutics received 68 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 65.52% of users gave Trevi Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
In the previous week, Trevi Therapeutics had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Trevi Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Trevi Therapeutics' average media sentiment score of 1.22 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the news media.
Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
Calliditas Therapeutics AB (publ) presently has a consensus price target of $39.25, suggesting a potential downside of 1.88%. Trevi Therapeutics has a consensus price target of $9.31, suggesting a potential upside of 147.67%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than Calliditas Therapeutics AB (publ).
Summary
Trevi Therapeutics beats Calliditas Therapeutics AB (publ) on 15 of the 18 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TRVI) was last updated on 1/20/2025 by MarketBeat.com Staff
